Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Google execs convened 'all-hands' meeting last week to address AI unit reorganizations amid staff concerns - Reuters
• Grok Bot launches in early beta for select subscribers
• Nebius soars on second quarter revenue beat